Study of Originator (IFX, REMICADE) or Biosimilars (RENFLEXIS, IFX-abda and INFLECTRA, IFX-dyyb) in Clinical Gastroenterology Practice
Latest Information Update: 22 Dec 2022
At a glance
- Drugs Infliximab (Primary) ; Infliximab (Primary) ; Infliximab (Primary)
- Indications Ankylosing spondylitis; Behcet's syndrome; COVID 2019 infections; Crohn's disease; Mucocutaneous lymph node syndrome; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- 22 Dec 2022 New trial record
- 26 Oct 2022 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022